{"doi":"10.1002/cam4.71220","title":"A Phase <scp>II</scp> Pilot Study of Anti‐ <scp>PD</scp> ‐ <scp>L1</scp> , Durvalumab, and a <scp>PARP</scp> Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation","abstract":"BACKGROUND: Immunostimulatory effects of PARP inhibitors could increase sensitivity to immune checkpoint inhibitors. The previous Phase II trial (MEDIOLA) reported clinical benefits of durvalumab and olaparib (D + O) in patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer. Yet, the clinical activity of D + O in germline BRCA wild-type (gBRCAwt) triple-negative breast cancer (TNBC) remains unknown. METHODS: This single-arm Phase II study tested D + O in patients with metastatic TNBC. The primary objective was overall response rate (ORR). Secondary objectives were safety, disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). Based on gBRCA status, patients were assigned to either gBRCAwt or gBRCAm cohort and were treated with D (1500 mg iv q4w) and O (300 mg twice a day orally). Pretreatment fresh tissues and serial blood samples were collected for correlative studies. RESULTS: Fifteen patients (12 gBRCAwt and 3 gBRCAm) were enrolled. gBRCAm and gBRCAwt cohorts are reported as a combined dataset because of small sample size due to COVID-19 and slow accrual. The median number of prior therapies was three (range 0-8). Among 14 RECIST-evaluable patients (11 gBRCAwt and 3 gBRCAm), ORR was 28.6% (3 gBRCAm and 1 gBRCAwt). DCR was 64.3% (3 gBRCAm and 6 gBRCAwt). The median PFS and OS were 3.6 months (95% confidence interval [CI]: 1.8-5.7) and 10.7 months (95% CI: 5.9-38.9), respectively. There is one gBRCAm patient with ongoing durable PR (67.4+ months). There was no new safety concern. CD83 expression on Types 1 and 2 conventional dendritic cells in blood at baseline was low in the patients with PFS ≥ 4 months compared to those with PFS < 4 months. CONCLUSION: Our study demonstrated modest clinical benefits of D + O with ORR of 28.6% in subsets of heavily pretreated TNBC. Further detailed classification of DCs to understand the predictive role of DCs and prospective validation in a large cohort is required. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02484404.","journal":"Cancer Medicine","year":2025,"id":537488,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":1,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9569,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02484404"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":242495,"name":"Ashley Cimino‐Mathews","orcid":"0000-0002-0638-7969","position":1,"is_corresponding":false},{"id":242501,"name":"Stanley Lipkowitz","orcid":"0000-0002-6103-2255","position":2,"is_corresponding":false},{"id":268299,"name":"Min-Jung Lee","orcid":"0000-0003-3943-8133","position":3,"is_corresponding":false},{"id":242496,"name":"Jayakumar R. Nair","orcid":"0000-0002-4478-4607","position":4,"is_corresponding":false},{"id":1423725,"name":"B. Brooke Solarz","orcid":null,"position":5,"is_corresponding":false},{"id":242493,"name":"Alexandra S. Zimmer","orcid":"0000-0001-6789-0982","position":6,"is_corresponding":false},{"id":238359,"name":"Bernadette Redd","orcid":"0000-0001-9058-9485","position":7,"is_corresponding":false},{"id":464856,"name":"Elliot Levy","orcid":null,"position":8,"is_corresponding":false},{"id":812530,"name":"Shraddha Rastogi","orcid":"0000-0003-0680-0407","position":9,"is_corresponding":false},{"id":1208614,"name":"N Sato","orcid":"0009-0007-1772-3183","position":10,"is_corresponding":false},{"id":560390,"name":"Ann McCoy","orcid":"0000-0002-0990-3252","position":11,"is_corresponding":false},{"id":109203,"name":"Seth M. Steinberg","orcid":"0000-0002-8280-551X","position":12,"is_corresponding":false},{"id":880602,"name":"Jung‐Min Lee","orcid":"0000-0003-1280-5909","position":13,"is_corresponding":false},{"id":1178513,"name":"Takeo Fujii","orcid":"0000-0003-3747-2688","position":0,"is_corresponding":true}],"reference_count":56,"raw_metadata":null,"created_at":"2026-07-19T02:52:12.997494Z","pmid":"41360639","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}